Key result
Elevated plasma H-FABP is linked to ~29% higher incident CHD risk, especially with lower omega-3 levels.
Why the study?
Evidence regarding associations of plasma heart-type fatty acid-binding protein with long-term risk of cardiac events and its interaction with omega-3 fatty acids in the general population remains scarce.
Are elevated plasma levels of H-FABP associated with a higher risk of incident CHD and HF in the general population, and is this modified by omega-3 fatty acids?
Cohort (n=42,392)
Are elevated plasma levels of H-FABP associated with a higher risk of incident CHD and HF in the general population, and is this modified by omega-3 fatty acids?
Elevated plasma H-FABP is associated with a higher risk of incident CHD and HF in the general population, predominantly among individuals with low levels of omega-3 fatty acids.
Answers are grounded in this paper and cite their sources.
H-FABP elevation was associated with higher cardiac event risk mainly at low omega-3 levels; leaves open utility for risk stratification pending prospective validation.
Background Heart-type fatty acid-binding protein (H-FABP), a principal intracellular transporter of long-chain fatty acids (FAs), has been investigated as an early diagnostic biomarker for acute myocardial infarction (MI) and acute coronary syndrome. However, evidence regarding its associations with long-term risk of cardiac events and potential interaction with omega-3 FAs remains scarce. Therefore, we aimed to investigate these associations in the general population. Methods This study included 42 392 participants from the UK Biobank who were free of coronary heart disease (CHD) and heart failure (HF) at baseline. Plasma levels of H-FABP were quantified using the Olink platform. Multivariable Cox regression was used to evaluate the associations of H-FABP with incident CHD and HF, considering potential interaction with omega-3 FAs. Results Elevated H-FABP levels were consistently associated with a higher risk of CHD (HR T3 vs T1 =1.29), MI (HR T3 vs T1 =1.54), CHD-related mortality (HR T3 vs T1 =2.04) and HF (HR T3 vs T1 =1.95) (all P-trend values <0.001). These associations appeared to be modified by plasma levels of omega-3 FAs, especially so for CHD (P-interaction=0.014) and MI (P-interaction=0.003). Comparing the extreme tertiles of H-FABP, HRs (95% CI) of CHD and MI were 1.41 (1.15 to 1.74) and 2.23 (1.57 to 3.15), respectively, among participants with lower omega-3 FAs, and 1.15 (0.96 to 1.38) and 1.11 (0.83 to 1.50), respectively, among those with higher omega-3 FAs. Conclusions Higher plasma levels of H-FABP were associated with a higher risk of CHD and HF in the general population, predominantly among individuals with low levels of omega-3 FAs.
No takes yet. Share an insight, caveat, or question.
Lyu et al. (2026) conducted a cohort in General population free of CHD and HF (n=42,392). Elevated plasma heart-type fatty acid-binding protein (H-FABP) vs. Lower levels of H-FABP (T1) was evaluated on incident CHD (HR 1.29, p=<0.001). Elevated plasma H-FABP levels were associated with a higher risk of incident CHD, an association that was stronger among individuals with lower omega-3 fatty acid levels.
Synapse has enriched 10 related papers. Consider them for comparative context: